



PRESS RELEASE

Axxam executes agreement with NYU Langone Medical Center for the provision of drug discovery services

October 14th, 2015 - Axxam SpA (Milan/Italy), a leading provider of discovery services has entered into a multi-year agreement with the Office of Therapeutics Alliances (OTA) of NYU Langone Medical Center (New York, US) to provide drug discovery expertise to advance their innovative pipeline of therapeutic programs. OTA is a drug discovery accelerator that provides resources to NYU Langone scientists to help translate their laboratory research into therapeutic discovery and a formal path towards the development of novel, FDA-approved drugs.

The goal of this collaboration is to develop specialized drug discovery assays for novel disease targets in OTA's portfolio of projects. Under the agreement, NYU Langone has access to Axxam's expertise in assay development, industrial high throughput screening and Axxam's novel compound collection, Axx^{Div2.0}. The alliance builds on Axxam's long history of working with many of the world's most prestigious academic institutions, disease foundations and biotech/pharmaceutical companies.

Stefan Lohmer, PhD, CEO of Axxam, commented: "Axxam is very pleased to start this collaboration with NYU Langone, one of the most prestigious academic medical centers in the US and to see this agreement as a further validation for our focus on innovative high quality science and continuous investments in our capabilities to translate targets into drug candidates. We are extremely impressed about the quality of the target portfolio generated from the scientists at NYU Langone and look forward to working together to set the ground for new therapies".

Nadim Shohdy, PhD, Director of OTA, commented: "The OTA model is to de-risk early, therapeutic projects from NYU Langone by combining our faculty's deep-seated expertise in novel disease pathways with the drug discovery expertise of key industry players such as Axxam. As such, we are excited about initiating projects with Axxam and working together to efficiently advance them to a stage far more validated to enable quality partnerships with biopharma, investors and disease foundations".

For more information about Axxam, or to speak with Dr. Lohmer, please contact Sabrina Corazza at +39 02 2105634 or sabrina.corazza.sc@axxam.com.

About Axxam SpA (www.axxam.com)

Axxam SpA is a privately owned contract research and discovery company located at the Science Park Openzone in Bresso (Milan, Italy). The Company is a leading provider of integrated discovery services for the entire Life Sciences industries as: Pharmaceutical, Crop protection, Animal health, Cosmetics and Nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies including: assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.